{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-21-017355","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.230324+00:00","generated_at":"2026-06-28T12:44:24.747721+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precigen reports Phase 1 data: 50% AML ORR, 40% HPV ORR; cash $181.3M","bullets":["50% ORR (3/6) in relapsed/refractory AML at low dose levels of PRGN-3006 UltraCAR-T in Phase 1 lymphodepletion cohort.","40% ORR (2/5) and 60% DCR (3/5) in recurrent/metastatic HPV-associated cancer with PRGN-2009 AdenoVerse combination arm.","PRGN-3006 and PRGN-3005 show no dose-limiting toxicities or neurotoxicity; durable expansion and persistence observed.","Cash, equivalents, and investments totaled $181.3M at Sep 30, 2021; net cash used in ops $41.2M (9 months, vs $60.6M prior year).","PRGN-3006 abstract selected for oral presentation at 63rd ASH Annual Meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-21-017355","json":"https://secwatch.observer/filing/0000950103-21-017355.json","markdown":"https://secwatch.observer/filing/0000950103-21-017355.md","text":"https://secwatch.observer/filing/0000950103-21-017355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010321017355/0000950103-21-017355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010321017355/dp161305_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:44:24.747721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}